• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索医疗保健人员在个性化肿瘤医学方面的知识、障碍和创新方法:一项范围综述

Exploring healthcare personnel's knowledge, barriers, and innovative approaches in personalised oncology medicine: a scoping review.

作者信息

Shrestha Shibu, Watts Gemma, Geiger Susi

机构信息

School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

School of Business, University College Dublin, Dublin, Ireland.

出版信息

Crit Public Health. 2025 Jun 28;35(1):2520410. doi: 10.1080/09581596.2025.2520410. eCollection 2025.

DOI:10.1080/09581596.2025.2520410
PMID:40757103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12315847/
Abstract

Personalised medicine is widely utilised in oncology, and healthcare personnel are its main gatekeepers and implementers. This scoping review provides insights into the knowledge and attitudes of healthcare personnel toward personalised medicine for cancer, barriers and challenges faced, and innovative practices employed for the provision of personalised medicine. Extensive database searches identified 19,972 studies, of which 50 studies were included in the final review. The data was charted by two reviewers and analysed thematically. The knowledge of healthcare personnel of personalised medicine was mixed, with some studies reporting overall good knowledge ( = 2) while some reported poor knowledge among healthcare personnel ( = 4). There was high interest (63-95%) in furthering education and training in personalised medicine ( = 6). The commonly reported barriers and challenges were: limited reimbursement and insurance coverage mechanism ( = 11); insufficient education and training ( = 10); and lack of trained personnel to provide the service ( = 7). The innovations identified emphasised enhancing the skills and capacity of the existing workforce as well as using technologies to assist in timely decision-making. Overall, gaps were identified at the human resource, institutional, and systemic levels, which will need to be addressed to improve the provision of personalised medicine and healthcare personnel's confidence levels.

摘要

个性化医疗在肿瘤学中得到广泛应用,医护人员是其主要把关者和实施者。本范围综述深入探讨了医护人员对癌症个性化医疗的知识和态度、面临的障碍与挑战以及提供个性化医疗所采用的创新做法。通过广泛的数据库检索,共识别出19972项研究,其中50项研究纳入最终综述。数据由两名评审员制表并进行主题分析。医护人员对个性化医疗的了解参差不齐,一些研究报告称总体了解情况良好(n = 2),而另一些研究则报告医护人员的了解情况较差(n = 4)。对个性化医疗继续教育和培训的兴趣很高(63%-95%)(n = 6)。常见的障碍和挑战包括:报销和保险覆盖机制有限(n = 11);教育和培训不足(n = 10);缺乏提供该服务的专业人员(n = 7)。所确定的创新措施强调提高现有工作人员的技能和能力,以及利用技术辅助及时决策。总体而言,在人力资源、机构和系统层面均发现了差距,需要加以解决,以改善个性化医疗的提供情况和医护人员的信心水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13a1/12315847/31fcf22eac37/CCPH_A_2520410_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13a1/12315847/38dabf5c277f/CCPH_A_2520410_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13a1/12315847/31fcf22eac37/CCPH_A_2520410_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13a1/12315847/38dabf5c277f/CCPH_A_2520410_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13a1/12315847/31fcf22eac37/CCPH_A_2520410_F0002_C.jpg

相似文献

1
Exploring healthcare personnel's knowledge, barriers, and innovative approaches in personalised oncology medicine: a scoping review.探索医疗保健人员在个性化肿瘤医学方面的知识、障碍和创新方法:一项范围综述
Crit Public Health. 2025 Jun 28;35(1):2520410. doi: 10.1080/09581596.2025.2520410. eCollection 2025.
2
Personalised risk communication for informed decision making about taking screening tests.关于进行筛查测试的明智决策的个性化风险沟通。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD001865. doi: 10.1002/14651858.CD001865.pub2.
3
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施:系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.
4
Personalised risk communication for informed decision making about taking screening tests.关于进行筛查测试的明智决策的个性化风险沟通。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD001865. doi: 10.1002/14651858.CD001865.pub3.
5
Personalised risk communication for informed decision making about entering screening programs.个性化风险沟通,以便就参与筛查项目做出明智决策。
Cochrane Database Syst Rev. 2003(1):CD001865. doi: 10.1002/14651858.CD001865.
6
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications.针对患者及护理人员的干预措施,以提高对镰状细胞病的认识及其相关并发症的识别能力。
Cochrane Database Syst Rev. 2016 Oct 6;10(10):CD011175. doi: 10.1002/14651858.CD011175.pub2.
7
Sexual Harassment and Prevention Training性骚扰与预防培训
8
How to Implement Digital Clinical Consultations in UK Maternity Care: the ARM@DA Realist Review.如何在英国产科护理中实施数字临床会诊:ARM@DA实证主义综述
Health Soc Care Deliv Res. 2025 May 21:1-77. doi: 10.3310/WQFV7425.
9
Digital augmentation of aftercare for patients with anorexia nervosa: the TRIANGLE RCT and economic evaluation.神经性厌食症患者后期护理的数字化增强:TRIANGLE随机对照试验及经济评估
Health Technol Assess. 2025 Jul;29(31):1-162. doi: 10.3310/ADLS3672.
10
Stakeholders' perceptions and experiences of factors influencing the commissioning, delivery, and uptake of general health checks: a qualitative evidence synthesis.利益相关者对影响一般健康检查的委托、提供和接受因素的看法与体验:一项定性证据综合分析
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD014796. doi: 10.1002/14651858.CD014796.pub2.

本文引用的文献

1
Will Precision Medicine Meet Digital Health? A Systematic Review of Pharmacogenomics Clinical Decision Support Systems Used in Clinical Practice.精准医学能否与数字健康相结合?临床实践中应用的药物基因组学临床决策支持系统的系统评价。
OMICS. 2024 Sep;28(9):442-460. doi: 10.1089/omi.2024.0131. Epub 2024 Aug 13.
2
Knowledge, attitudes, and practices of primary healthcare practitioners in low- and middle-income countries: a scoping review on genetics.低收入和中等收入国家初级医疗保健从业者的知识、态度和实践:一项关于遗传学的范围综述
J Community Genet. 2024 Oct;15(5):461-474. doi: 10.1007/s12687-024-00721-y. Epub 2024 Aug 9.
3
Reducing the costs of blockbuster gene and cell therapies in the Global South.
降低全球南方地区重磅基因和细胞疗法的成本。
Nat Biotechnol. 2024 Jan;42(1):8-12. doi: 10.1038/s41587-023-02049-3.
4
Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations.中东和非洲国家转移性去势抵抗性前列腺癌的管理:挑战与战略建议。
Urol Ann. 2022 Oct-Dec;14(4):303-313. doi: 10.4103/ua.ua_148_21. Epub 2022 Jul 22.
5
General practitioners' (GPs) experience, attitudes and needs on clinical genetic services: a systematic review.全科医生(GP)对临床遗传服务的经验、态度和需求:系统评价。
Fam Med Community Health. 2022 Nov;10(4). doi: 10.1136/fmch-2021-001515.
6
Cancer genomic medicine in Japan and the roles of pharmacists.日本的癌症基因组医学与药剂师的作用。
Pharmacogenet Genomics. 2022 Aug 1;32(6):242-245. doi: 10.1097/FPC.0000000000000476. Epub 2022 Jun 9.
7
Physicians' experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece.医生在基因检测和遗传咨询方面的经验、实践和教育:希腊全国调查研究。
Fam Cancer. 2022 Oct;21(4):479-487. doi: 10.1007/s10689-022-00290-4. Epub 2022 Jan 24.
8
Community oncologists' perceptions and utilization of large-panel genomic tumor testing.社区肿瘤学家对大panel 基因组肿瘤检测的认知和应用。
BMC Cancer. 2021 Nov 25;21(1):1273. doi: 10.1186/s12885-021-08985-0.
9
The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey.澳大利亚医学肿瘤学家将综合基因组分析纳入临床护理的经验与需求:一项全国性调查。
Oncotarget. 2021 Oct 12;12(21):2169-2176. doi: 10.18632/oncotarget.28076.
10
Clinician perspectives on communication and implementation challenges in precision oncology.临床医生对精准肿瘤学中沟通和实施挑战的看法。
Per Med. 2021 Sep;18(6):559-572. doi: 10.2217/pme-2021-0048. Epub 2021 Oct 22.